Mandate

Vinge advises Lunar in connection with the transfer of all customer relationships within its P2P business to SaveLend

April 11, 2023 Financial Regulatory M&A

Vinge advises Lunar Bank A/S in connection with the transfer of all customer relationships with investors and lenders within its P2P business and related trademark and domain names to SaveLend Group AB’s subsidiary SBL Finans AB (publ).

The transfer includes approximately 17,000 active investors, 7,000 active borrowers and an invested capital of approximately MSEK 450. Lunar has operated its P2P business since 2021. In order to streamline its business, Lunar has actively been looking for a new home for its P2P customers, both investors and borrowers. Through the transaction, all customer relationships will as of closing be taken over and managed through SaveLend Group’s own platform and customer service team. 

Completion is subject to the approval of the Danish Financial Supervisory Authority.

Vinge’s team mainly consisted of Filip Öhrner, Robin Fagerström (M&A) and Caroline Krassén (Financial Services).

 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025